Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>Resources>White Papers>This White Paper
  White Papers
Scientific News
Experimental MERS Vaccine Shows Promise in Animal Studies
A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines.
Young South African Women can Adhere to Daily PrEP Regimen as HIV Prevention
NIH-funded study finds men in Bangkok, Harlem also successful in taking daily dose.
Researchers Find Key Player in Diabetic Kidney Disease Through Power of Metabolomics
Discovery could lead to new and better diagnostic marker for chronic kidney disease.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Santhera Announces First Patient Dosing with Omigapil in CMD
Company announces full patient recruitment of CALLISTO study.
Study Shows Promise of Precision Medicine for Most Common Type of Lymphoma
The study appeared online July 20, 2015, in Nature Medicine.
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Early Antiretroviral Therapy Prevents Non-AIDS Outcomes in HIV-infected People
NIH-supported findings illustrate manifold benefit of therapy.
Adaptimmune’s NY-ESO-1 TCR-engineered T-Cells Demonstrate Durable Persistence
Study has been published in Nature Medicine.
Scroll Up
Scroll Down

Speeding up time-to-market
Bookmark and Share

Vetter Pharma International GmbH

In the hyper-competitive pharmaceuticals and biotechnology markets, companies face a litany of challenges, from stricter regulatory guidelines and rising development costs to the pressures of globalization. To succeed under these conditions, pharmaceuticals and biotech firms are finding it critical to reduce their time-tomarket, thus creating competitive advantage and maximizing near-term sales.

Unfortunately, the actual time required to develop a new product is not easy to shorten. Sometimes, however, firms can streamline the product transfer phase of development, speeding the time to commercial production. Both experience and expertise are critical in developing the correct methodology, which allows for significant reduction of development time while maintaining product quality.

Further Information

Related Content

Vetter Development Service Chicago Completes Recent On-Site Expansion Activities
Continued demand and increased customer product transfers are generating a positive business outlook for the company’s early-stage development facility.
Thursday, June 11, 2015
Vetter Serializes the First Product for South Korea
CDMO produces clearly identifiable labelling for a top-ten pharmaceutical company.
Saturday, May 02, 2015
Vetter Appoints Oliver Albrecht as Managing Director
Role with company commenced on April 1, 2015.
Thursday, April 09, 2015
Vetter Continues to Expand Capacity
Structural work completed on Vetter’s new multi-functional building for its Development Service and information technology (IT).
Friday, January 30, 2015
Vetter Adds Flexible Serialization Service to its Portfolio
A new service allowing for the explicit identification of drug packaging.
Thursday, December 04, 2014
Vetter Announces Opening of Office to Support Growing Asian Healthcare Market
New Asia Pacific office will support customer relations and the development of new business.
Friday, November 21, 2014
Vetter Announces Personnel Changes in its Development Service Division
Clinical manufacturing services continue to attract new business.
Saturday, October 18, 2014
Vetter Continues to Strengthen its Market Position
Another positive year for the CDMO.
Wednesday, January 15, 2014
Vetter to Construct New Filling Lines to Expand Capacity
Responding to customer demand and company growth.
Thursday, October 10, 2013
Vetter’s Newest Facility Successfully Completes FDA Inspection
Center for visual inspection and logistics sets high safety and control standards.
Thursday, March 28, 2013
Vetter Receives “Known Consignor” Approval from Germany's Federal Aviation Office
The CDMO meets new requirements six months ahead of deadline.
Wednesday, December 12, 2012
Vetter Receives Top Prize at the European Outsourcing Awards Ceremony
CDMO clinches an industry Oscar for its innovative high-speed filling line.
Friday, October 12, 2012
Vetter’s Development Service Doubles its Revenues and Grows its Capabilities
Ravensburg development labs add enhanced technologies.
Friday, September 28, 2012
Vetter Prepares for Further Growth
A leading CDMO secures triple-digit million euro credit facility.
Tuesday, May 01, 2012
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!